PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
4 hedge funds and large institutions have $13K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
333% more capital invested
Capital invested by funds: $3K → $13K (+$10K)
100% more funds holding
Funds holding: 2 → 4 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BO
BRR OpCo
Columbus,
Ohio
|
+$3K |
| 2 |
FWM
Focused Wealth Management
Newburgh,
New York
|
+$1K |
Top Sellers
PVCT Hedge Fund Activity: Q4 2017 in Review
4 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q4 2017, worth a combined $13K — up 333% from $3K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PVCT positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BRR OpCo, opening a new position worth an estimated $3K.
- 4 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q4 2017, up from 2 in Q3 2017.
- Funds reported $13K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q4 2017, up 333% quarter-over-quarter.
- 2 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q4 2017 and 0 closed out, a net change of +2 holders.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q4 2017 was BRR OpCo, an estimated $3K added.
Based on aggregated 13F filings for Q4 2017.